JENA, Germany, Oct. 21, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced its participation in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference. Details are as follows: Guggenheim Securities 2nd Annual Healthcare Innovation ConferenceNovember 10 - 12, 2025 in Boston, MAFireside chat on November 11 at 2:30 PM ET InflaRx will also conduct one-on-one investor meetin ...

Core Points - InflaRx N.V. has regained compliance with Nasdaq's minimum bid price requirement as of September 11, 2025, after its ordinary shares closed at $1.00 or greater for 10 consecutive business days from August 27, 2025, to September 10, 2025 [1][2] Company Overview - InflaRx N.V. is a biopharmaceutical company focused on developing anti-inflammatory therapeutics by targeting the complement system, specifically through its proprietary anti-C5a and anti-C5a receptor technologies [3] - The company has developed vilobelimab, a first-in-class anti-C5a monoclonal antibody that has shown disease-modifying clinical activity and tolerability in multiple studies [3] - InflaRx is also working on INF904, an orally administered small molecule inhibitor targeting C5a-induced signaling via the C5a receptor [3] - Founded in 2007, InflaRx has offices in Jena and Munich, Germany, and Ann Arbor, MI, USA [4]

Company Overview - InflaRx N.V. is a biopharmaceutical company focused on developing anti-inflammatory therapeutics by targeting the complement system [3] - The company has developed vilobelimab, a first-in-class anti-C5a monoclonal antibody, which has shown disease-modifying clinical activity and tolerability in multiple studies [3] - InflaRx is also working on INF904, an orally administered small molecule inhibitor of C5a-induced signaling [3] Upcoming Events - InflaRx will participate in the Cantor Global Healthcare Conference from September 3 to 5, 2025, with a fireside chat scheduled for September 4 at 9:10 AM ET [1] - The company will also conduct one-on-one investor meetings on September 4 during the Cantor conference [1] - Additionally, InflaRx will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8 to 10, 2025, with a presentation on September 9 at 3:30 PM ET [2] - One-on-one investor meetings will also take place on September 9 at the H.C. Wainwright conference [2]

Company Overview - InflaRx N.V. is a biopharmaceutical company focused on developing anti-inflammatory therapeutics by targeting the complement system [2] - The company utilizes proprietary anti-C5a and anti-C5a receptor technologies to create specific inhibitors of the complement activation factor C5a [2] - InflaRx has developed vilobelimab, a first-in-class anti-C5a monoclonal antibody, which has shown disease-modifying clinical activity in multiple studies [2] Upcoming Financial Results - InflaRx will report its second quarter 2025 financial and operating results on August 7, 2025, before the market opens [1] - No conference call is planned for this earnings report [1] Product Development - InflaRx is also developing INF904, an orally administered small molecule inhibitor targeting C5a-induced signaling [2] - The company was founded in 2007 and has offices in Jena and Munich, Germany, as well as Ann Arbor, MI, USA [2][3]

Core Points - InflaRx N.V. has received a notice from Nasdaq indicating that its common shares have closed below the minimum bid price of $1.00 for the last 30 consecutive business days [1] - The company has until January 7, 2026, to regain compliance with the Minimum Bid Price Rule, with the possibility of transferring to the Nasdaq Capital Market for an additional compliance period [2] - The notice does not have an immediate effect on the listing or trading of the company's shares, and InflaRx plans to monitor its share price and explore options for compliance [3] Company Overview - InflaRx is a biopharmaceutical company focused on developing anti-inflammatory therapeutics by targeting the complement system, specifically through its proprietary anti-C5a and anti-C5a receptor technologies [4] - The company has developed vilobelimab, a first-in-class anti-C5a monoclonal antibody, and is also working on INF904, an orally administered small molecule inhibitor [4] - Founded in 2007, InflaRx has offices in Jena and Munich, Germany, and Ann Arbor, MI, USA [5]

Core Insights - InflaRx N.V. is a biopharmaceutical company focused on developing anti-inflammatory therapeutics targeting the complement system [1][5] - The company will participate in several investor conferences in June and July 2025, including presentations and one-on-one meetings [1][2][3][4] Company Overview - InflaRx specializes in anti-C5a and anti-C5aR technologies to create inhibitors for the complement activation factor C5a, which is linked to various inflammatory diseases [5] - The lead product candidate, vilobelimab, is a first-in-class anti-C5a monoclonal antibody that has shown clinical activity and tolerability in multiple studies [5] - InflaRx is also developing INF904, an orally administered small molecule inhibitor of the C5a receptor [5] - The company was founded in 2007 and has offices in Jena and Munich, Germany, as well as Ann Arbor, MI, USA [5][6] Upcoming Events - InflaRx will present at the Jefferies Global Healthcare Conference from June 3-5, 2025, with a presentation scheduled for June 4 at 7:35 AM ET [2] - The company will participate in the Oppenheimer Innovators in I&I Summit on June 25, 2025, focusing on advances in dermatology [3] - InflaRx will also attend the Leerink Partners Therapeutics Forum on July 8-9, 2025, with one-on-one investor meetings on June 8 [4]

Company Overview - InflaRx N.V. is a biopharmaceutical company focused on developing anti-inflammatory therapeutics by targeting the complement system [2] - The company utilizes proprietary anti-C5a and anti-C5aR technologies to create specific inhibitors of the complement activation factor C5a and its receptor C5aR [2] - InflaRx's lead product candidate, vilobelimab, is a first-in-class, intravenously delivered anti-C5a monoclonal antibody that has shown clinical activity and tolerability in various studies [2] Upcoming Financial Reporting - InflaRx will report its first quarter 2025 financial and operating results on May 7, 2025, before the market opens [1] - No conference call is planned for this financial report [1] Subsidiaries - InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. [3]

Core Insights - InflaRx N.V. presented multiple data sets at the 2025 American Academy of Dermatology Annual Meeting, highlighting the potential of vilobelimab in treating inflammatory conditions such as pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS) [1][2] Group 1: Vilobelimab in Pyoderma Gangrenosum (PG) - Safety data from a Phase 2a dose-finding study indicated that adverse events (AEs) were mostly mild to moderate, with vilobelimab being well tolerated across all doses [3] - Pharmacokinetic (PK) and pharmacodynamic (PD) analyses showed a significant reduction in C5a concentrations, with approximately 90% reduction observed by Day 15 across all dose groups [4] - The ongoing Phase 3 trial is utilizing vilobelimab dosed at 2400 mg bi-weekly to suppress C5a in ulcerative PG patients [4] Group 2: Vilobelimab in Hidradenitis Suppurativa (HS) - A post-hoc analysis from the Phase 2b SHINE trial demonstrated vilobelimab's effectiveness in reducing draining tunnels (dT) by 63.2% compared to 18.0% for placebo, with a 3.1x relative improvement in complete resolution of dT [5] - Safety analysis showed that vilobelimab was well tolerated, with similar rates and severity of AEs compared to placebo [6] - PK/PD analysis indicated that administration of 800 mg vilobelimab resulted in significant reductions in C5a concentrations, which remained lower than baseline during follow-up [7]